BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ioka T, Kanai M, Kobayashi S, Sakai D, Eguchi H, Baba H, Seo S, Taketomi A, Takayama T, Yamaue H, Takahashi M, Sho M, Kamei K, Fujimoto J, Toyoda M, Shimizu J, Goto T, Shindo Y, Yoshimura K, Hatano E, Nagano H; Kansai Hepatobiliary Oncology Group (KHBO). Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci 2023;30:102-10. [PMID: 35900311 DOI: 10.1002/jhbp.1219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Inoue H, Aimono E, Kasuga A, Tanaka H, Iwasaki A, Saya H, Arima Y. Pixel-Level Clustering of Hematoxylin-Eosin-Stained Sections of Mouse and Human Biliary Tract Cancer. Biomedicines 2022;10. [PMID: 36551889 DOI: 10.3390/biomedicines10123133] [Reference Citation Analysis]
2 Delaye M, Lièvre A, Neuzillet C. Apport de l'immunothérapie dans le traitement des cancers des voies biliaires avancés. Bulletin du Cancer 2022;109:11S11-11S20. [DOI: 10.1016/s0007-4551(22)00464-7] [Reference Citation Analysis]
3 Bai XS, Zhou SN, Jin YQ, He XD. Combining of chemotherapy with targeted therapy for advanced biliary tract cancer: A systematic review and meta-analysis. World J Gastrointest Oncol 2022; 14(10): 2061-2076 [DOI: 10.4251/wjgo.v14.i10.2061] [Reference Citation Analysis]
4 Takahara N, Nakai Y, Isayama H, Sasaki T, Morine Y, Watanabe K, Ueno M, Ioka T, Kanai M, Kondo S, Okano N, Koike K. A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer.. [DOI: 10.21203/rs.3.rs-2075157/v1] [Reference Citation Analysis]